Business Model (API Manufacturing)Lasa's core B2B API manufacturing model provides durable, contract-driven revenue from pharmaceutical customers. Supplying bulk drugs and intermediates creates sticky, repeat demand and scale advantages for production know-how, supporting long-term cash generation if operational performance recovers.

Industry PositioningOperating in specialty and generic APIs exposes Lasa to structural secular demand: aging populations and generic substitution drive stable outsourcing of API production. This market structure supports long-term demand for contract API suppliers despite company-specific execution challenges.

Balance Sheet LeverageReported moderate leverage and a relatively strong equity ratio indicate financial flexibility versus highly indebted peers. Manageable debt levels reduce immediate solvency risk, providing runway to restructure operations or secure working capital while addressing profitability and cash flow shortfalls.

Bears Say

Declining RevenuesSustained revenue decline materially erodes operating scale and pricing leverage. A near-term trend of shrinking top line and persistent losses reduces ability to invest in product development, retain customers, and absorb cost volatility, threatening long-term competitiveness unless growth reverses.

Negative Cash FlowNegative operating and free cash flow constrain working capital and capital expenditure capacity, forcing reliance on external financing or asset sales. Over months this undermines operational continuity, limits investments to restore margins, and increases liquidity and refinancing risk.

Margin DeteriorationWorsening gross and net margins and negative EBIT/EBITDA highlight structural cost or pricing problems. Persistently low margins weaken cash conversion and capital return potential, indicating the need for structural cost cuts, product-mix improvement, or pricing power restoration to achieve sustainable profitability.

Lasa Supergenerics Ltd. News

Exchange Seeks Clarification From Lasa Supergenerics on Q3 FY2025 Results

The latest update is out from Lasa Supergenerics Ltd. ( ($IN:LASA) ). The stock exchange has requested clarification...

6d ago

LASA

Lasa Supergenerics Reinforces Compliance with SDD Certification

Lasa Supergenerics Ltd. ( ($IN:LASA) ) has issued an update. Lasa Supergenerics Ltd. has issued a compliance certificate...

5M ago

LASA

Lasa Supergenerics Announces Key Decisions from Board Meeting

Lasa Supergenerics Ltd. ( ($IN:LASA) ) has issued an announcement. Lasa Supergenerics Ltd. held a board meeting on...

6M ago

LASA

Lasa Supergenerics Promoter Maintains Shareholding Stability

An announcement from Lasa Supergenerics Ltd. ( ($IN:LASA) ) is now available. Lasa Supergenerics Ltd. has announced that...

11M ago

LASA

LASA FAQ

What was Lasa Supergenerics Ltd.’s price range in the past 12 months?

Lasa Supergenerics Ltd. lowest stock price was ₹7.13 and its highest was ₹22.70 in the past 12 months.

What is Lasa Supergenerics Ltd.’s market cap?

Lasa Supergenerics Ltd.’s market cap is ₹365.24M.

When is Lasa Supergenerics Ltd.’s upcoming earnings report date?

Lasa Supergenerics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 76 days.

How were Lasa Supergenerics Ltd.’s earnings last quarter?

Lasa Supergenerics Ltd. released its earnings results on Feb 13, 2026. The company reported -₹0.51 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.51.

Is Lasa Supergenerics Ltd. overvalued?

According to Wall Street analysts Lasa Supergenerics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lasa Supergenerics Ltd. pay dividends?

Lasa Supergenerics Ltd. pays a Annually dividend of ₹0.25 which represents an annual dividend yield of N/A. See more information on Lasa Supergenerics Ltd. dividends here

What is Lasa Supergenerics Ltd.’s EPS estimate?

Lasa Supergenerics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lasa Supergenerics Ltd. have?

Lasa Supergenerics Ltd. has 50,101,240 shares outstanding.

What happened to Lasa Supergenerics Ltd.’s price movement after its last earnings report?

Lasa Supergenerics Ltd. reported an EPS of -₹0.51 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.032%.

Which hedge fund is a major shareholder of Lasa Supergenerics Ltd.?

Currently, no hedge funds are holding shares in IN:LASA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lasa Supergenerics Ltd.

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers veterinary and other API products, anthelmintic products, animal feed ingredients, and reagents for therapeutic use. The company also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India.